{"id":743295,"date":"2026-02-05T05:10:12","date_gmt":"2026-02-05T05:10:12","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/743295\/"},"modified":"2026-02-05T05:10:12","modified_gmt":"2026-02-05T05:10:12","slug":"university-of-liverpool-to-use-ai-to-accelerate-new-medicine-discovery","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/743295\/","title":{"rendered":"University of Liverpool to use AI to accelerate new medicine discovery"},"content":{"rendered":"

Artificial Intelligence will be used to accelerate new medicine discovery in a University of Liverpool partnership secured following Mayor Steve Rotheram\u2019s US trade mission.<\/p>\n

The University of Liverpool will work with Boston-based BPGbio, Inc. to harness large-scale healthcare data to accelerate the development of new treatments.<\/p>\n

The collaboration, conducted through the University\u2019s Civic HealthTech Innovation Zone (CHI-Zone), will use advanced computer techniques to\u00a0analyse a wide range of health information \u2013 such as medical scans, lab results, and detailed biological\u00a0data about genes and proteins \u2013 alongside patient outcomes. Scientists hope\u00a0to uncover cause-and-effect links in disease processes that could point to new drugs.<\/p>\n

Professor Iain Buchan, Professor Claire Eyres and Dr Peter Green from\u00a0the University of Liverpool joined Mayor Rotheram in a high-level meeting with BPGbio President and CEO Dr Niven Narain and colleagues during a Liverpool City Region trade mission to Boston in October 2024.<\/p>\n

The success of the trip has led to the latest investment, which will create jobs in the region and further strengthen the University of Liverpool and city region\u2019s place in the global health-tech sector.<\/p>\n

\"\"Credit: University of Liverpool<\/p>\n

BPGbio, Inc. is a leading US company that uses AI to develop new medicines. The collaboration\u00a0will significantly expand and enhance its\u00a0NAi\u00ae \u2018Bayesian AI\u2019 platform \u2013 an advanced AI system designed to identify what drives diseases. Led by an interdisciplinary team at the University of Liverpool, the collaboration will advance the platform\u2019s speed, scalability, and utility across drug discovery and precision healthcare.<\/p>\n

Professor Iain Buchan, W.H. Duncan Chair in Public Health Systems, Associate Pro Vice Chancellor for Innovation, Director of Civic Health Innovation Labs, and Principal Investigator of the program, added:<\/p>\n

\u201cThe CHI-Zone is bringing together industry and civic partners to create and evaluate data-intensive solutions to some of society\u2019s most challenging health problems.\u00a0Biology and healthcare urgently need AI systems that can generate understanding how diseases work, not just correlations. Our collaboration with BPGbio, Inc. brings together cutting-edge Bayesian computation, multi-omics research, and secure data environments to deliver exactly that. This is the blueprint for the next generation of precision medicine.\u201d<\/p>\n

Niven R. Narain, Ph.D., President and CEO, BPGbio said:<\/p>\n

\u201cNAi\u00ae has already helped us discover actionable drug targets and advance new therapies in oncology, mitochondrial disease, and neurology. This collaboration with the University of Liverpool will take the platform to a new level\u2014as omic data generation has now advanced to the signal cell level, where causality is ideally suited to make massive advancements.<\/p>\n

\u201cBy combining BPGbio\u2019s biology-first philosophy with Liverpool\u2019s unmatched expertise in causal inference and computational science, we are building the future of mechanism-based drug discovery and an informed data driven healthcare ecosystem. Medicine and healthcare solutions fail not because of a lack of data, but instead because we don\u2019t let human biology guide the path, since we are all very different and nothing should be a one size fits all solution\u201d<\/p>\n

\"\"Credit: University of Liverpool
\nSteve Rotheram, Mayor of the Liverpool City Region, said:\u00a0<\/p>\n

\u201cThis partnership is a direct outcome of our visit to the US and another strong example of growing American investment in the Liverpool City Region \u2013 and the importance of bilateral relationships.<\/p>\n

\u201cFollowing in the footsteps of companies like Kyndryl, which launched its UK hub in Liverpool last year, this is a major vote of confidence in our universities, our talent, and our ambition to become a global leader in health and life sciences.<\/p>\n

\u201cMy ambition is for the Liverpool City Region to be the global home of AI for Good\u00a0\u2013 not chasing AI for its own sake, but backing innovation that genuinely improves the health of our people, strengthens our communities, and creates high-quality jobs.<\/p>\n

\u201cGlobal businesses are recognising what we already know: the Liverpool City Region is not just open for business \u2013 it\u2019s open for innovation.\u201d<\/p>\n

The Civic HealthTech Innovation Zone (CHI-Zone) is funded by the Liverpool City Region Life Sciences Innovation Zone Programme which forms part of the Government\u2019s national Investment Zone Programme, positioning the city region as a powerhouse for health and life sciences innovation.<\/p>\n

Visit the University of Liverpool website here.<\/a>
\nFind out the latest in Liverpool here.<\/a><\/p>\n

Find out what\u2019s good up North on our new platform, The Northern Guide.<\/strong>\u00a0<\/p>\n

From the best hotels, beauty spots, days out, food and more up North \u2013 visit\u00a0thenorthernguide.com<\/a>\u00a0and follow The Northern Guide on Instagram\u00a0HERE.<\/a><\/p>\n